论文部分内容阅读
观察藻酸双酯钠（ＰＳＳ）对肾病综合症和实验性原位性肾炎的影响。肾病综合症（ＮＳ）Ⅰ型患者 ３５人，治疗组１８例，对照组１７例，治疗组除加用 ＰＳＳ外，其它治疗同对照组；阳离子化牛血清蛋白（Ｃ—ＢＳＡ）建立原位性肾炎模型，用ＰＳＳ进行治疗ＮＳ患者用ＰＳＳ治疗能明显减轻尿蛋白，降低血胆固醇和甘油三酯，减少深静脉血栓形成的机会；ＰＳＳ能干扰原位性肾炎模型的建立，干扰组没有出现明显肾小球病变，大鼠无明显蛋白尿，而模型组则出现明显肾小球病变，大量尿蛋白和肾功能减退。ＰＳＳ能干扰实验性原位性肾炎形成；临床上ＰＳＳ治疗ＮＳ 患者能减轻尿蛋白，其机理可能是ＰＳＳ干扰免疫复合物（ＩＣ）在肾小球沉积。
To observe the effect of sodium alginate (PSS) on nephrotic syndrome and experimental oto-nephritis. 35 patients with type 1 nephrotic syndrome (NS), 18 patients in the treatment group and 17 patients in the control group were treated with PSS, while the other treatments were the same as those in the control group. Cationicated bovine serum albumin (C-BSA) Nephritis model, treatment with PSS NS patients treated with PSS can significantly reduce urinary protein, lower blood cholesterol and triglycerides, reduce the chance of deep venous thrombosis; PSS can interfere with the establishment of in situ nephritis model, the interference group did not appear obvious Glomerular lesions, no obvious proteinuria in rats, while the model group showed significant glomerular lesions, a large number of urinary protein and renal dysfunction. PSS can interfere with the formation of experimental in situ nephritis; clinical treatment of NS patients with PSS can reduce urinary protein, the mechanism may be PSS interference immune complexes (IC) in the glomerular deposition.